Excitement fills the air as Neuralink, a pioneering company, announces its receipt of FDA approval to commence the groundbreaking first-in-human clinical study on May 28th, 2023 ! This milestone achievement is the fruit of the tireless efforts of the Neuralink team, working in close collaboration with the FDA, and marks a significant stride towards a future where our technology can offer assistance to numerous individuals. While the recruitment process for our clinical trial is yet to commence, we assure you that further details will be announced in due course, providing interested parties with comprehensive information. For those unfamiliar with this extraordinary technology, here are several key points that shed light on the remarkable benefits of connecting the human brain with computers. Definition of Brain-Computer Interfaces (BCIs): Brain-computer interfaces, or BCIs, are innovative systems that establish a direct communication pathway be...
What to do When You Don't Have Gold Standard Images to Compare Your Processed Images How to Measure the Quality of Images When You Don't Have Gold Standard Images to Compare In the realm of image analysis and processing, quantifying image quality forms a crucial cornerstone of various methodologies. This is especially true when there's a lack of gold standard images or ground truth to set the benchmark. In such scenarios, we're often left asking: how can we measure image quality objectively or subjectively? Let's delve into this topic with an emphasis on establishing robust and reliable metrics for image quality analysis. Objective Measurement of Image Quality Without Ground Truth Objective quality metrics quantify the difference between two images based on numerical methods. But, how do we assess image quality objectivel...